Primary immunodeficiency disorders (PIDs) are a group of genetic defects characterized by
abnormalities of one or more components of the immune system. While there have been …

Background X-linked agammaglobulinemia is an inherited immunodeficiency recognized
since 1952. In spite of seven decades of experience, there is still a limited understanding of …

Abstract Primary Immunodeficiency Diseases (PIDs) are increasingly being reported across
the World. Several advances have been made in the diagnostic and therapeutic research …

Background There is paucity of literature on XLA from developing countries. Herein we
report the clinical and molecular profile and outcome in a multicenter cohort of patients with …

Immunoglobulin replacement therapy enhances survival and reduces infection risk in
patients with agammaglobulinaemia. We hypothesized that despite regular immunoglobulin …

Purpose We conducted a systematic review and meta-regression analysis to evaluate the
impact of increasing immunoglobulin G (IgG) trough levels on the clinical outcomes in …

Immunoglobulins (Ig) were used as a therapeutic modality for the first time in a patient with X-
linked agammaglobulinemia in 1952 by Colonel Ogden Bruton, decades before the …

Abstract Background/Objectives Patients with primary antibody deficiency (PAD) are
predisposed to develop meningoencephalitis, often considered to be enteroviral. However …

X-linked agammaglobulinemia (XLA) is a primary disorder of humoral immunity
characterized by Bruton tyrosine kinase gene mutations resulting in a primary antibody …

Aim: This post hoc analysis evaluated the efficacy and overall tolerability of immunoglobulin
(Ig) treatment modalities (intravenous Ig [iv. Ig], subcutaneous Ig [sc. Ig] and facilitated sc. Ig …